Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 Expression

Viral Diseases, Roche Palo Alto, Palo Alto, CA.

^* To whom correspondence should be addressed. E-mail: Changhua.ji{at}roche.com.

	Abstract

In the current study, a novel coreceptor-specific cell-cell fusion (CCF) assay system is reported. The system possesses the following features: dual CCR5-dependent and CXCR4-dependent CCF assays, all stable cell lines, inducible expression of gp160 to minimize cytotoxicity, robust luciferase reporter, and 384-well format. These assays have been validated using various known HIV entry inhibitors targeting various stages of the HIV entry/fusion process, including fusion inhibitors, gp120 inhibitors, CCR5 antagonists, CCR5 antibodies, and CXCR4 antagonists. IC₅₀ data generated from this assay system were well correlated to that from the antiviral assays. The effects of DMSO on this assay system were assessed, and a 2- to 3-fold increase in luciferase activity was observed in the presence of 0.05% to 2% DMSO. Although cell-cell fusion efficiency was enhanced, no changes in drug response kinetics for entry inhibitors were found in the presence of 0.1% or 0.5% DMSO. This assay system has been successfully used for the identification and characterization of thousands of CCR5 inhibitors.

Key Words: HIV, cell-cell fusion, DMSO, luciferase reporter, entry inhibitor

First published on November 28, 2005, doi:10.1177/1087057105282959

Journal of Biomolecular Screening 2006;11:65.

A more recent version of this article appeared on February 1, 2006


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Ji, E. Kopetzki, A. Jekle, K.-G. Stubenrauch, X. Liu, J. Zhang, E. Rao, T. Schlothauer, S. Fischer, N. Cammack, et al. CD4-anchoring HIV-1 Fusion Inhibitor with Enhanced Potency and in Vivo Stability J. Biol. Chem., February 20, 2009; 284(8): 5175 - 5185. [Abstract] [Full Text] [PDF]

				C. Lackman-Smith, C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R. G. Ptak, R. W. Buckheit Jr., et al. Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1768 - 1781. [Abstract] [Full Text] [PDF]

				R. Kondru, J. Zhang, C. Ji, T. Mirzadegan, D. Rotstein, S. Sankuratri, and M. Dioszegi Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists Mol. Pharmacol., March 1, 2008; 73(3): 789 - 800. [Abstract] [Full Text] [PDF]

				L. Cai and M. Gochin A Novel Fluorescence Intensity Screening Assay Identifies New Low-Molecular-Weight Inhibitors of the gp41 Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2388 - 2395. [Abstract] [Full Text] [PDF]

				C. Ji, J. Zhang, M. Dioszegi, S. Chiu, E. Rao, A. deRosier, N. Cammack, M. Brandt, and S. Sankuratri CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor Mol. Pharmacol., July 1, 2007; 72(1): 18 - 28. [Abstract] [Full Text] [PDF]

				J. Zhang, E. Rao, M. Dioszegi, R. Kondru, A. DeRosier, E. Chan, S. Schwoerer, N. Cammack, M. Brandt, S. Sankuratri, et al. The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1386 - 1397. [Abstract] [Full Text] [PDF]

				E. Chan, G. Heilek-Snyder, N. Cammack, S. Sankuratri, and C. Ji Development of a Moloney Murine Leukemia Virus-Based Pseudotype Anti-HIV Assay Suitable for Accurate and Rapid Evaluation of HIV Entry Inhibitors J Biomol Screen, September 1, 2006; 11(6): 652 - 663. [Abstract] [PDF]